全文获取类型
收费全文 | 999篇 |
免费 | 56篇 |
国内免费 | 10篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 19篇 |
基础医学 | 54篇 |
口腔科学 | 38篇 |
临床医学 | 143篇 |
内科学 | 432篇 |
皮肤病学 | 10篇 |
神经病学 | 57篇 |
特种医学 | 79篇 |
外科学 | 68篇 |
综合类 | 11篇 |
一般理论 | 2篇 |
预防医学 | 75篇 |
眼科学 | 14篇 |
药学 | 41篇 |
肿瘤学 | 7篇 |
出版年
2023年 | 4篇 |
2022年 | 4篇 |
2021年 | 6篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 17篇 |
2017年 | 10篇 |
2016年 | 12篇 |
2015年 | 16篇 |
2014年 | 27篇 |
2013年 | 40篇 |
2012年 | 49篇 |
2011年 | 41篇 |
2010年 | 31篇 |
2009年 | 36篇 |
2008年 | 47篇 |
2007年 | 48篇 |
2006年 | 32篇 |
2005年 | 45篇 |
2004年 | 36篇 |
2003年 | 51篇 |
2002年 | 43篇 |
2001年 | 25篇 |
2000年 | 34篇 |
1999年 | 39篇 |
1998年 | 26篇 |
1997年 | 38篇 |
1996年 | 36篇 |
1995年 | 23篇 |
1994年 | 25篇 |
1993年 | 21篇 |
1992年 | 8篇 |
1991年 | 17篇 |
1990年 | 9篇 |
1989年 | 18篇 |
1988年 | 16篇 |
1987年 | 15篇 |
1986年 | 15篇 |
1985年 | 12篇 |
1984年 | 7篇 |
1983年 | 16篇 |
1982年 | 20篇 |
1981年 | 16篇 |
1980年 | 8篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1972年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有1065条查询结果,搜索用时 312 毫秒
31.
Spijkerman AM Henry RM Dekker JM Nijpels G Kostense PJ Kors JA Ruwaard D Stehouwer CD Bouter LM Heine RJ 《Journal of internal medicine》2004,256(5):429-436
OBJECTIVES: Screening for type 2 diabetes has been recommended and targeted screening might be an efficient way to screen. The aim was to investigate whether diabetic patients identified by a targeted screening procedure differ from newly diagnosed diabetic patients in general practice with regard to the prevalence of macrovascular complications. DESIGN: Cross-sectional population-based study. SETTING: Population study, primary care. SUBJECTS: Diabetic patients identified by a population-based targeted screening procedure (SDM patients), consisting of a screening questionnaire and a fasting capillary glucose measurement followed by diagnostic testing, were compared with newly diagnosed diabetic patients in general practice (GPDM patients). Ischaemic heart disease and prior myocardial infarction were assessed by ECG recording. Peripheral arterial disease was assessed by the ankle-arm index. Intima-media thickness of the right common carotid artery was measured with ultrasound. RESULTS: A total of 195 SDM patients and 60 GPDM patients participated in the medical examination. The prevalence of MI was 13.3% (95% CI 9.3-18.8%) and 3.4% (1.0-11.7%) in SDM patients and GPDM patients respectively. The prevalence of ischaemic heart disease was 39.5% (95% CI 32.9-46.5%) in SDM patients and 24.1% (15.0-36.5%) in GPDM patients. The prevalence of peripheral arterial disease was similar in both groups: 10.6% (95% CI 6.9-15.9%) and 10.2% (4.7-20.5%) respectively. Mean intima-media thickness was 0.85 mm (+/-0.17) in SDM patients and 0.90 mm (+/-0.20) in GPDM patients. The difference in intima-media thickness was not statistically significant. CONCLUSIONS: Targeted screening identified patients with a prevalence of macrovascular complications similar to that of patients detected in general practice, but with a lower degree of hyperglycaemia. 相似文献
32.
33.
Agostino Consoli MD Leszek Czupryniak MD Rui Duarte MD György Jermendy MD Alexandra Kautzky-Willer MD Chantal Mathieu MD Miguel Melo MD Ofri Mosenzon MD Frank Nobels MD Nikolaos Papanas MD Gabriela Roman MD Oliver Schnell MD Alexis Sotiropoulos MD Coen D. A. Stehouwer MD Cees J. Tack MD Vincent Woo MD Gian Paolo Fadini MD Itamar Raz MD 《Diabetes, obesity & metabolism》2020,22(10):1705-1713
The large number of pharmacological agents available to treat type 2 diabetes (T2D) makes choosing the optimal drug for any given patient a complex task. Because newer agents offer several advantages, whether and when sulphonylureas (SUs) should still be used to treat T2D is controversial. Published treatment guidelines and recommendations should govern the general approach to diabetes management. However, expert opinions can aid in better understanding local practices and in formulating individual choices. The current consensus paper aims to provide additional guidance on the use of SUs in T2D. We summarize current local treatment guidelines in European countries, showing that SUs are still widely proposed as second-line treatment after metformin and are often ranked at the same level as newer glucose-lowering medications. Strong evidence now shows that sodium-glucose co-transporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with low hypoglycaemia risk, promote weight loss, and exert a positive impact on vascular, cardiac and renal endpoints. Thus, using SUs in place of SGLT-2is and GLP-1RAs may deprive patients of key advantages and potentially important cardiorenal benefits. In subjects with ascertained cardiovascular disease or at very high cardiovascular risk, SGLT-2is and/or GLP-1RAs should be used as part of diabetes management, in the absence of contraindications. Routine utilization of SUs as second-line agents continues to be acceptable in resource-constrained settings. 相似文献
34.
35.
van Greevenbroek MM Jacobs M van der Kallen CJ Blaak EE Jansen EH Schalkwijk CG Feskens EJ Stehouwer CD 《International journal of cardiology》2012,154(2):158-162
Background
Complement C3 is an emerging risk factor for coronary heart disease (CHD) and is particularly increased in the metabolic syndrome. A direct effect of smoking on structure and function of complement C3 has been suggested.Hypothesis
Smoking behavior may affect the cardiovascular risk that is associated with plasma complement C3.Methods
The association between plasma C3 and CHD was studied in the CODAM (Cohort on Diabetes and Atherosclerosis Maastricht) study population (n = 562, 61% male) with examination of effect modification by smoking.Results
The overall prevalence of CHD was 23.3%. Higher plasma C3 levels were associated with a higher CHD prevalence, and there was a significant interaction with heavy smoking (p = 0.01). In never & light smokers, the univariate OR for CHD per 1 s.d. (0.33 g/L) increase in C3 was 1.09 [95% confidence interval (CI) 0.85-1.41] (p = 0.505) whereas in heavy smokers it was 2.05 [1.43-2.93] (p < 0.001). The association in the group of heavy smokers remained significant (OR 2.38 [1.54-3.68], p < 0.001) after adjustment for traditional risk factors for cardiovascular disease and also after further adjustment for other cardiometabolic risk factors, i.e. the metabolic syndrome, CRP and insulin resistance (HOMA2IR) (OR C3 between 2.16 and 2.29, all p ≤ 0.001).Conclusion
Human plasma complement C3 is associated with prevalent CHD, but only in heavy smokers, and this association is independent of important metabolic cardiovascular risk factors. 相似文献36.
37.
38.
E. A. C. de Waard A. Koster T. Melai T. A. van Geel R. M. A. Henry M. T. Schram P. C. Dagnelie C. J. van der Kallen S. J. S. Sep C. D. A. Stehouwer N. C. Schaper S. Köhler H. H. C. M. Savelberg P. P. M. M. Geusens J. P. W. van den Bergh 《Osteoporosis international》2016,27(11):3207-3216
Summary
In this cohort of relatively young and well-treated participants with type 2 diabetes, we found no association between diabetes status and a history of previous fractures and recent falls. Furthermore, no association between diabetes severity and previous fractures or recent falls was found.Introduction
In this study, we examined the association between glucose metabolism status and historical fractures or recent falls and the effect of diabetes severity (glucose control, insulin use, and diabetes duration) on falls and fractures in the participants with type 2 diabetes.Methods
Cross-sectional data from 2005 participants of the Maastricht Study. Falls in the past 6 months and fractures ≥age 50 were assessed by questionnaire. Glucose metabolism status (normal glucose metabolism, impaired glucose metabolism, or type 2 diabetes) was based on the oral glucose tolerance test and medication use.Results
In the completely adjusted model, the odds for a fall were not significantly higher in those with impaired glucose metabolism status (OR (95%CI) 1.28 (0.93–1.77)) or with type 2 diabetes (OR (95%CI) 1.21 (0.80–1.81)) compared with the group with normal glucose metabolism. Within the group with type 2 diabetes, there were no significant differences with regard to reported falls between participants with HbA1c >7 % (53 mmol/mol) versus HbA1c ≤7 % (OR (95%CI) 1.05 (0.58–1.90)), insulin users versus non-insulin users (OR (95%CI) 1.51 (0.79–2.89)), and with a diabetes duration >5 versus ≤5 years (OR (95%CI) 0.52 (0.46–1.47)). Similarly, neither glucose metabolism status nor diabetes severity was associated with prior fractures.Conclusions
Glucose metabolism status was not significantly associated with previous fractures and recent falls. In addition, in this cohort of relatively young and well-treated participants with type 2 diabetes, diabetes severity was not associated with previous fractures and recent falls.39.
Coen van Guldener Prabath W B Nanayakkara Coen D A Stehouwer 《Clinical chemistry and laboratory medicine》2007,45(12):1683-1687
Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is formed by methylation of arginine residues in proteins and released after proteolysis. In this reaction, S-adenosylmethionine is methyldonor and S-adenosylhomocysteine the demethylated product. ADMA and homocysteine are thus biochemically linked. Both plasma homocysteine and ADMA concentrations are increased in patients with renal dysfunction, probably as a result of an impairment in their metabolic, but not urinary, clearance. Hyperhomocysteinemia has been associated with an increased risk of cardiovascular disease in end-stage renal disease, especially in patients without malnutrition and inflammation. Also, plasma ADMA levels have been associated with cardiovascular disease in renal failure patients. Both homocysteine and ADMA are thought to mediate their adverse vascular effects by impairing endothelial, nitric oxide-dependent function resulting in decreased vasodilatation, increased smooth muscle cell proliferation, platelet dysfunction and increased monocyte adhesion. At the same time, it has been shown that the correlation between plasma ADMA and homocysteine is weak and that, in renal patients, the association of plasma ADMA carotid intima-media thickness, cardiovascular events and overall mortality is independent of homocysteine. This indicates that the negative vascular effects of ADMA and homocysteine have a different etiology. Treatment with folic acid substantially lowers homocysteine, but not ADMA concentration. So far, homocysteine-lowering therapy has not been very successful in decreasing cardiovascular disease. In patients with renal failure, ADMA reduction may be an interesting new goal in the prevention of cardiovascular disease. 相似文献
40.